Format

Send to

Choose Destination
J Gen Intern Med. 2004 Jun;19(6):638-45.

Suboptimal statin adherence and discontinuation in primary and secondary prevention populations.

Author information

1
Department of Pharmacy Services, University of Michigan Hospitals and Health Centers, Ann Arbor, Michigan, USA. ellisj2@ccf.org

Abstract

OBJECTIVES:

To compare statin nonadherence and discontinuation rates of primary and secondary prevention populations and to identify factors that may affect those suboptimal medication-taking behaviors.

DESIGN:

Retrospective cohort utilizing pharmacy claims and administrative databases.

SETTING:

A midwestern U.S. university-affiliated hospital and managed care organization (MCO).

PATIENTS:

Non-Medicaid MCO enrollees, 18 years old and older, who filled 2 or more statin prescriptions from January 1998 to November 2001; 2258 secondary and 2544 primary prevention patients were identified.

MEASUREMENTS:

Nonadherence was assessed by the percent of days without medication (gap) over days of active statin use, a measurement known as cumulative multiple refill-interval gap (CMG). Discontinuation was identified by cessation of statin refills prior to the end of available pharmacy claims data.

RESULTS:

On average, the primary and secondary groups went without medication 20.4% and 21.5% of the time, respectively (P=.149). Primary prevention patients were more likely to discontinue statin therapy relative to the secondary prevention cohort (relative risk [RR], 1.24; 95% confidence interval [CI], 1.08 to 1.43). Several factors influenced nonadherence and discontinuation. Fifty percent of patients whose average monthly statin copayment was < US dollars 10 discontinued by the end of follow-up (3.9 years), whereas 50% of those who paid >US dollars 10 but <or=US dollars 20 and >US dollars 20 discontinued by 2.2 and 1.0 years, respectively (RR, 1.39 and 4.30 relative to <US dollars 10 copay, respectively).

CONCLUSIONS:

Statin nonadherence and discontinuation was suboptimal and similar across prevention categories. Incremental efforts, including those that decrease out-of-pocket pharmaceutical expenditures, should focus on improving adherence in high-risk populations most likely to benefit from statin use.

PMID:
15209602
PMCID:
PMC1492382
DOI:
10.1111/j.1525-1497.2004.30516.x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center